A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Jiangsu HengRui Medicine Co., Ltd.64 enrolled

Overview

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) for advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for advanced malignant tumors of patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Solid Tumors

Interventions

Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)DRUG

Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female aged ≥18 years and ≤75 years at the time of signing the ICF; 2. Dose Escalation Period: Histopathologically documented incurable advanced malignancies with standard treatment failure; 3. At least one measurable lesion that meets RECIST 1.1 criteria in case of solid tumors; 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 5. Life expectancy ≥3 months; 6. Adequate organ functions as defined; 7. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study. Exclusion Criteria: 1. The imaging examinations shows the tumor invades large blood vessels; Or as the assessment of the investigator, the tumor is highly likely to invade important blood vessels which would cause fatal bleeding during treatment; 2. The imaging examinations shows significant pulmonary cavitary tumors occurs with the bleeding risk as the investigator's assessment; 3. patients with active brain metastasis (without medical control or with clinical symptoms), cancerous meningitis, or spinal cord compression; 4. Uncontrollable pleural effusion, pericardial effusion or peritoneal effusion, with clinical symptoms; 5. Severe bong injury caused by metastatic tumor of bone; 6. Prior malignancy (other than current malignant tumor) within 3 years before the first dose of study treatment; 7. History of autoimmune diseases; 8. Evidence or history of arterial/venous thrombosis within 6 months before the first dose; 9. Patients with interstitial pneumonitis or interstitial lung disease; past history of interstitial pneumonitis or interstitial lung disease requiring hormone therapy; 10. When receiving immune checkpoint inhibitors previously, myocarditis related with immune, ≥ grade 2 of pneumonia related with immune or ≥ grade 3 of other adverse reactions related with immune occurred.

Locations (1)

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Dose Limited Toxicity

Dose Limited Toxicity of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound)

Time frame: first dose of study medication up to 21 days]

Recommended phase II dose

The Recommended phase II dose of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound)

Time frame: first dose of study medication up to 21 days

ORR

Objective Response Rate, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, or initiation of other anti-tumor treatment, whichever occurs first, up to 6 months

Secondary Outcomes

DoR

Duration of response, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the firstly documented tumor response (evaluated based on RECIST v1.1 criteria) to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

DCR

Disease control rate, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

PFS

Progression-free survival, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, up to 6 months

Overall survival, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose to the date of death for any reason, up to 100 months

12 months' survival rate

Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose up to 12 months

TTF

Time to Failure, Efficacy endpoints of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Time frame: from the date of the first dose to the date of treatment termination, up to 6 months

Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame: from signature completion of ICF to 90 days after the last dose or to the beginning of the new anti-cancer therapy, up to 6 months

The occurrence rate of dose titration

The occurrence rate of dose interruption, dose decrease and dose termination because of study drug related toxicity during the study

Time frame: from signature completion of ICF to 90 days after the last dose or to the beginning of the new anti-cancer therapy, up to 6 months

concentration of drug in serum

PK concentration of Camrelizumab for Injection

Time frame: 0.5 hour before first dose of Camrelizumab for Injection to 30 days after last dose

concentration of drug in plasma

PK concentration of Famitinib malate capsule and its intermediate metabolite, and Paclitaxel For Injection(Albumin Bound)